Share Price and Basic Stock Data
Last Updated: December 27, 2025, 8:49 pm
| PEG Ratio | 5.28 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fortis Healthcare Ltd operates in the Hospitals and Medical Services industry, with a current share price of ₹902 and a market capitalization of ₹68,127 Cr. The company has shown steady revenue growth, with reported sales rising from ₹5,718 Cr in FY 2022 to ₹6,298 Cr in FY 2023 and projected to reach ₹6,893 Cr in FY 2024. The trailing twelve months (TTM) sales stood at ₹8,434 Cr, indicating robust operational performance. Quarterly sales also reflect this upward trajectory, increasing from ₹1,488 Cr in Jun 2022 to ₹1,657 Cr in Jun 2023, and further to ₹1,770 Cr in Sep 2023. This consistent growth is vital in an industry where demand for healthcare services is rising, especially in urban areas. The company’s operating profit margin (OPM) averaged 19% in FY 2023, showcasing its ability to manage costs effectively while increasing revenue, a critical factor in maintaining competitiveness in the healthcare sector.
Profitability and Efficiency Metrics
Fortis Healthcare’s profitability metrics demonstrate a healthy operational efficiency, with a reported net profit of ₹1,038 Cr for FY 2025. The return on equity (ROE) stood at 10.1%, and the return on capital employed (ROCE) was 12%, reflecting effective utilization of shareholder funds and capital resources. The company’s net profit margin improved to 10.25% in FY 2025, up from 9.22% in FY 2024, indicating enhanced profitability relative to revenue. The interest coverage ratio (ICR) was reported at 8.97x, suggesting that Fortis can comfortably meet its interest obligations, which is essential for financial stability. However, the operating profit margin (OPM) fluctuated, with a high of 23% in FY 2025 but lower averages in previous quarters, which could raise concerns about cost management in fluctuating demand conditions. Overall, these metrics indicate a solid operational foundation but highlight the need for consistent cost control.
Balance Sheet Strength and Financial Ratios
Fortis Healthcare’s balance sheet exhibits a stable financial structure, with total borrowings at ₹3,195 Cr and reserves amounting to ₹8,674 Cr as of Sep 2025. The company’s debt-to-equity ratio stood at 0.24, reinforcing a conservative leverage stance compared to industry norms. The book value per share was reported at ₹118.11, providing a solid cushion for investors. The current ratio of 0.91 indicates that while Fortis has slightly less current assets than current liabilities, it remains within acceptable limits for operational liquidity. Additionally, the cash conversion cycle (CCC) improved to -101 days, suggesting efficient management of working capital. However, an increasing trend in borrowings, which rose from ₹926 Cr in FY 2023 to ₹2,475 Cr in FY 2025, may pose risks if not managed prudently, especially in a capital-intensive industry like healthcare.
Shareholding Pattern and Investor Confidence
Fortis Healthcare’s shareholding structure reflects a balanced distribution among various investor categories, with promoters holding 31.17%, foreign institutional investors (FIIs) at 27.90%, and domestic institutional investors (DIIs) at 29.14%. This diverse ownership base can enhance stability and investor confidence. The number of shareholders increased to 2,20,766 by Sep 2025, indicating rising interest in the stock. However, FIIs have shown a declining trend from 31.22% in Mar 2023 to 27.90% in Sep 2025, which could signal some caution from foreign investors regarding Fortis’s future prospects. The consistent promoter shareholding suggests confidence in the company’s long-term strategy, but the fluctuation in FII participation may warrant close monitoring. Overall, the shareholding pattern indicates a solid foundation but also highlights potential volatility in market sentiment.
Outlook, Risks, and Final Insight
Looking ahead, Fortis Healthcare is positioned to capitalize on the growing demand for healthcare services, supported by its revenue growth and profitability metrics. However, risks persist, including the rising level of borrowings and the potential impact of fluctuating operating margins. The company must navigate these challenges while continuing to enhance operational efficiency and manage costs effectively. Additionally, the healthcare sector faces regulatory scrutiny and competition, which could affect market share and profitability. If Fortis can maintain its growth trajectory and address its financial risks, it has the potential to strengthen its market position significantly. Conversely, failure to manage costs and debt levels may hinder its ability to sustain growth in a competitive landscape. The focus should remain on delivering quality healthcare services while optimizing financial management to ensure long-term sustainability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 44.8 Cr. | 134 | 187/120 | 9.14 | 117 | 2.62 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 24.5 Cr. | 23.4 | 35.5/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 7.90 Cr. | 7.64 | 20.8/7.08 | 87.8 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 112 Cr. | 59.9 | 98.7/55.2 | 24.8 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.8 Cr. | 3.67 | 7.29/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,411.86 Cr | 696.56 | 92.72 | 93.18 | 0.33% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,488 | 1,607 | 1,560 | 1,643 | 1,657 | 1,770 | 1,680 | 1,786 | 1,859 | 1,988 | 1,928 | 2,007 | 2,167 |
| Expenses | 1,237 | 1,304 | 1,283 | 1,372 | 1,386 | 1,440 | 1,396 | 1,405 | 1,516 | 1,554 | 1,553 | 1,572 | 1,676 |
| Operating Profit | 251 | 303 | 276 | 271 | 272 | 330 | 284 | 381 | 343 | 435 | 375 | 435 | 491 |
| OPM % | 17% | 19% | 18% | 16% | 16% | 19% | 17% | 21% | 18% | 22% | 19% | 22% | 23% |
| Other Income | 31 | 75 | 26 | 26 | 10 | 18 | 19 | 17 | 14 | -42 | 47 | -29 | 31 |
| Interest | 31 | 33 | 33 | 32 | 31 | 32 | 33 | 35 | 35 | 36 | 45 | 68 | 70 |
| Depreciation | 74 | 77 | 83 | 82 | 79 | 84 | 87 | 92 | 91 | 95 | 97 | 102 | 101 |
| Profit before tax | 176 | 268 | 186 | 183 | 171 | 233 | 183 | 271 | 230 | 261 | 279 | 237 | 351 |
| Tax % | 24% | 19% | 24% | 25% | 27% | 21% | 27% | 25% | 24% | 26% | 9% | 21% | 24% |
| Net Profit | 134 | 218 | 142 | 138 | 124 | 184 | 134 | 203 | 174 | 193 | 254 | 188 | 267 |
| EPS in Rs | 1.62 | 2.71 | 1.72 | 1.76 | 1.48 | 2.30 | 1.78 | 2.37 | 2.20 | 2.34 | 3.28 | 2.44 | 3.45 |
Last Updated: August 20, 2025, 10:45 am
Below is a detailed analysis of the quarterly data for Fortis Healthcare Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 2,167.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,007.00 Cr. (Mar 2025) to 2,167.00 Cr., marking an increase of 160.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,676.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,572.00 Cr. (Mar 2025) to 1,676.00 Cr., marking an increase of 104.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 491.00 Cr.. The value appears strong and on an upward trend. It has increased from 435.00 Cr. (Mar 2025) to 491.00 Cr., marking an increase of 56.00 Cr..
- For OPM %, as of Jun 2025, the value is 23.00%. The value appears strong and on an upward trend. It has increased from 22.00% (Mar 2025) to 23.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is 31.00 Cr.. The value appears strong and on an upward trend. It has increased from -29.00 Cr. (Mar 2025) to 31.00 Cr., marking an increase of 60.00 Cr..
- For Interest, as of Jun 2025, the value is 70.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 68.00 Cr. (Mar 2025) to 70.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 101.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 102.00 Cr. (Mar 2025) to 101.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 351.00 Cr.. The value appears strong and on an upward trend. It has increased from 237.00 Cr. (Mar 2025) to 351.00 Cr., marking an increase of 114.00 Cr..
- For Tax %, as of Jun 2025, the value is 24.00%. The value appears to be increasing, which may not be favorable. It has increased from 21.00% (Mar 2025) to 24.00%, marking an increase of 3.00%.
- For Net Profit, as of Jun 2025, the value is 267.00 Cr.. The value appears strong and on an upward trend. It has increased from 188.00 Cr. (Mar 2025) to 267.00 Cr., marking an increase of 79.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 3.45. The value appears strong and on an upward trend. It has increased from 2.44 (Mar 2025) to 3.45, marking an increase of 1.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:22 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,492 | 3,966 | 4,199 | 4,574 | 4,561 | 4,469 | 4,632 | 4,030 | 5,718 | 6,298 | 6,893 | 7,783 | 8,434 |
| Expenses | 3,430 | 3,857 | 4,106 | 4,220 | 4,287 | 4,238 | 4,022 | 3,626 | 4,649 | 5,196 | 5,625 | 6,195 | 6,576 |
| Operating Profit | 62 | 109 | 92 | 354 | 274 | 231 | 610 | 404 | 1,069 | 1,101 | 1,268 | 1,588 | 1,858 |
| OPM % | 2% | 3% | 2% | 8% | 6% | 5% | 13% | 10% | 19% | 17% | 18% | 20% | 22% |
| Other Income | 152 | 92 | 299 | 649 | -689 | 228 | 126 | 95 | 367 | 157 | 64 | -11 | 98 |
| Interest | 250 | 152 | 133 | 229 | 258 | 337 | 205 | 166 | 147 | 129 | 131 | 184 | 257 |
| Depreciation | 183 | 235 | 225 | 222 | 239 | 233 | 292 | 291 | 301 | 316 | 342 | 386 | 407 |
| Profit before tax | -219 | -185 | 34 | 552 | -912 | -110 | 239 | 43 | 988 | 814 | 858 | 1,007 | 1,292 |
| Tax % | 5% | 2% | -24% | 13% | 2% | 103% | 62% | 230% | 20% | 22% | 25% | 20% | |
| Net Profit | -218 | -130 | 42 | 479 | -934 | -224 | 91 | -56 | 790 | 633 | 645 | 809 | 1,038 |
| EPS in Rs | -4.73 | -3.10 | 0.40 | 8.14 | -19.46 | -3.96 | 0.77 | -1.45 | 7.35 | 7.80 | 7.93 | 10.26 | 13.43 |
| Dividend Payout % | -0% | -1% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 13% | 13% | 10% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 40.37% | 132.31% | 1040.48% | -294.99% | 76.02% | 140.62% | -161.54% | 1510.71% | -19.87% | 1.90% | 25.43% |
| Change in YoY Net Profit Growth (%) | 0.00% | 91.94% | 908.17% | -1335.47% | 371.01% | 64.61% | -302.16% | 1672.25% | -1530.59% | 21.77% | 23.53% |
Fortis Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 11% |
| 3 Years: | 11% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 70% |
| 3 Years: | 31% |
| TTM: | 43% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 48% |
| 3 Years: | 49% |
| 1 Year: | 69% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 6% |
| 3 Years: | 9% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 4:15 am
Balance Sheet
Last Updated: December 4, 2025, 1:15 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 463 | 463 | 463 | 518 | 519 | 755 | 755 | 755 | 755 | 755 | 755 | 755 | 755 |
| Reserves | 3,820 | 3,585 | 3,998 | 4,626 | 3,543 | 5,846 | 5,906 | 5,365 | 5,423 | 6,487 | 6,908 | 8,162 | 8,674 |
| Borrowings | 2,550 | 1,784 | 1,513 | 2,217 | 1,962 | 2,010 | 1,594 | 1,531 | 1,255 | 926 | 1,155 | 2,475 | 3,195 |
| Other Liabilities | 1,018 | 1,760 | 1,257 | 2,227 | 2,455 | 2,875 | 2,781 | 3,216 | 4,082 | 3,921 | 4,153 | 1,985 | 2,389 |
| Total Liabilities | 7,851 | 7,592 | 7,232 | 9,588 | 8,479 | 11,486 | 11,036 | 10,866 | 11,516 | 12,089 | 12,971 | 13,377 | 15,013 |
| Fixed Assets | 4,147 | 4,218 | 3,642 | 5,419 | 4,992 | 8,477 | 8,802 | 8,799 | 9,416 | 9,426 | 9,874 | 10,424 | 11,703 |
| CWIP | 147 | 228 | 226 | 268 | 226 | 450 | 204 | 165 | 193 | 228 | 542 | 407 | 306 |
| Investments | 1,817 | 1,464 | 1,452 | 1,878 | 1,732 | 270 | 175 | 186 | 104 | 210 | 230 | 169 | 220 |
| Other Assets | 1,739 | 1,682 | 1,913 | 2,023 | 1,529 | 2,290 | 1,856 | 1,716 | 1,803 | 2,225 | 2,326 | 2,378 | 2,784 |
| Total Assets | 7,851 | 7,592 | 7,232 | 9,588 | 8,479 | 11,486 | 11,036 | 10,866 | 11,516 | 12,089 | 12,971 | 13,377 | 15,013 |
Below is a detailed analysis of the balance sheet data for Fortis Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 755.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 755.00 Cr..
- For Reserves, as of Sep 2025, the value is 8,674.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,162.00 Cr. (Mar 2025) to 8,674.00 Cr., marking an increase of 512.00 Cr..
- For Borrowings, as of Sep 2025, the value is 3,195.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,475.00 Cr. (Mar 2025) to 3,195.00 Cr., marking an increase of 720.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2,389.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,985.00 Cr. (Mar 2025) to 2,389.00 Cr., marking an increase of 404.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 15,013.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 13,377.00 Cr. (Mar 2025) to 15,013.00 Cr., marking an increase of 1,636.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 11,703.00 Cr.. The value appears strong and on an upward trend. It has increased from 10,424.00 Cr. (Mar 2025) to 11,703.00 Cr., marking an increase of 1,279.00 Cr..
- For CWIP, as of Sep 2025, the value is 306.00 Cr.. The value appears to be declining and may need further review. It has decreased from 407.00 Cr. (Mar 2025) to 306.00 Cr., marking a decrease of 101.00 Cr..
- For Investments, as of Sep 2025, the value is 220.00 Cr.. The value appears strong and on an upward trend. It has increased from 169.00 Cr. (Mar 2025) to 220.00 Cr., marking an increase of 51.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,784.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,378.00 Cr. (Mar 2025) to 2,784.00 Cr., marking an increase of 406.00 Cr..
- For Total Assets, as of Sep 2025, the value is 15,013.00 Cr.. The value appears strong and on an upward trend. It has increased from 13,377.00 Cr. (Mar 2025) to 15,013.00 Cr., marking an increase of 1,636.00 Cr..
Notably, the Reserves (8,674.00 Cr.) exceed the Borrowings (3,195.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 60.00 | 108.00 | 91.00 | 352.00 | 273.00 | 229.00 | 609.00 | 403.00 | 0.00 | -925.00 | 0.00 | -1.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 46 | 38 | 39 | 38 | 38 | 44 | 36 | 41 | 33 | 34 | 33 | 37 |
| Inventory Days | 26 | 25 | 23 | 23 | 24 | 22 | 30 | 29 | 33 | 31 | 24 | 23 |
| Days Payable | 200 | 207 | 218 | 215 | 279 | 296 | 226 | 205 | 178 | 179 | 164 | 161 |
| Cash Conversion Cycle | -128 | -144 | -156 | -155 | -217 | -230 | -161 | -135 | -112 | -115 | -107 | -101 |
| Working Capital Days | -19 | -71 | -69 | -87 | -113 | -234 | -150 | -56 | -35 | -22 | -124 | -30 |
| ROCE % | 0% | -0% | 3% | 11% | 3% | 6% | 4% | 2% | 10% | 10% | 10% | 12% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid Cap Fund | 27,834,044 | 2.78 | 2558.23 | N/A | N/A | N/A |
| Kotak Midcap Fund | 24,724,343 | 3.76 | 2272.41 | N/A | N/A | N/A |
| Nippon India Growth Mid Cap Fund | 13,542,021 | 2.96 | 1244.65 | N/A | N/A | N/A |
| Axis Midcap Fund | 12,427,065 | 3.55 | 1142.17 | 12,674,257 | 2025-12-15 02:41:06 | -1.95% |
| HDFC Small Cap Fund | 9,440,132 | 2.28 | 867.64 | 9,973,132 | 2025-12-15 02:41:06 | -5.34% |
| DSP Mid Cap Fund | 5,152,245 | 2.39 | 473.54 | 5,166,727 | 2025-12-15 02:41:06 | -0.28% |
| Aditya Birla Sun Life ELSS Tax Saver Fund | 4,912,331 | 2.88 | 451.49 | 8,360,144 | 2025-12-07 02:17:25 | -41.24% |
| HDFC Large and Mid Cap Fund | 4,733,349 | 1.51 | 435.04 | N/A | N/A | N/A |
| Kotak Large & Midcap Fund | 4,200,000 | 1.29 | 386.02 | N/A | N/A | N/A |
| Sundaram Mid Cap Fund | 3,592,166 | 2.47 | 330.16 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 10.26 | 7.93 | 7.80 | 7.35 | -1.45 |
| Diluted EPS (Rs.) | 10.26 | 7.93 | 7.80 | 7.35 | -1.45 |
| Cash EPS (Rs.) | 15.68 | 12.96 | 12.28 | 14.13 | 2.48 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 118.11 | 113.33 | 107.30 | 92.83 | 88.98 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 118.11 | 113.33 | 107.30 | 92.83 | 88.98 |
| Revenue From Operations / Share (Rs.) | 103.09 | 91.30 | 83.42 | 75.73 | 53.38 |
| PBDIT / Share (Rs.) | 21.92 | 17.30 | 15.40 | 14.52 | 5.97 |
| PBIT / Share (Rs.) | 16.81 | 12.76 | 11.22 | 10.54 | 2.12 |
| PBT / Share (Rs.) | 13.19 | 11.24 | 10.49 | 12.76 | -0.05 |
| Net Profit / Share (Rs.) | 10.57 | 8.42 | 8.10 | 10.14 | -1.37 |
| NP After MI And SOA / Share (Rs.) | 10.26 | 7.93 | 7.80 | 7.35 | -1.45 |
| PBDIT Margin (%) | 21.26 | 18.94 | 18.46 | 19.17 | 11.19 |
| PBIT Margin (%) | 16.30 | 13.97 | 13.45 | 13.91 | 3.98 |
| PBT Margin (%) | 12.79 | 12.30 | 12.57 | 16.85 | -0.10 |
| Net Profit Margin (%) | 10.25 | 9.22 | 9.70 | 13.39 | -2.57 |
| NP After MI And SOA Margin (%) | 9.94 | 8.68 | 9.34 | 9.70 | -2.72 |
| Return on Networth / Equity (%) | 8.68 | 7.81 | 8.12 | 8.98 | -1.79 |
| Return on Capital Employeed (%) | 10.50 | 9.52 | 7.69 | 7.49 | 1.61 |
| Return On Assets (%) | 5.65 | 4.50 | 4.73 | 4.67 | -0.98 |
| Long Term Debt / Equity (X) | 0.23 | 0.09 | 0.07 | 0.12 | 0.15 |
| Total Debt / Equity (X) | 0.24 | 0.11 | 0.09 | 0.15 | 0.18 |
| Asset Turnover Ratio (%) | 0.57 | 0.53 | 0.09 | 0.07 | 0.05 |
| Current Ratio (X) | 0.91 | 0.44 | 0.98 | 0.89 | 0.84 |
| Quick Ratio (X) | 0.84 | 0.41 | 0.90 | 0.79 | 0.77 |
| Inventory Turnover Ratio (X) | 69.89 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 9.99 | 12.60 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 6.67 | 8.01 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 90.01 | 87.40 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 93.33 | 91.99 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 8.97 | 9.97 | 9.01 | 7.47 | 2.72 |
| Interest Coverage Ratio (Post Tax) (X) | 5.81 | 5.73 | 5.16 | 4.07 | 0.36 |
| Enterprise Value (Cr.) | 54674.02 | 32853.83 | 20823.69 | 23306.97 | 16352.45 |
| EV / Net Operating Revenue (X) | 7.03 | 4.77 | 3.31 | 4.08 | 4.06 |
| EV / EBITDA (X) | 33.04 | 25.16 | 17.90 | 21.26 | 36.26 |
| MarketCap / Net Operating Revenue (X) | 6.78 | 4.60 | 3.12 | 3.83 | 3.73 |
| Retention Ratios (%) | 90.00 | 87.39 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 5.91 | 4.14 | 2.71 | 3.55 | 2.45 |
| Price / Net Operating Revenue (X) | 6.78 | 4.60 | 3.12 | 3.83 | 3.73 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.02 | -0.01 |
After reviewing the key financial ratios for Fortis Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 10.26. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 10.26, marking an increase of 2.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 10.26. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 10.26, marking an increase of 2.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 15.68. This value is within the healthy range. It has increased from 12.96 (Mar 24) to 15.68, marking an increase of 2.72.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 118.11. It has increased from 113.33 (Mar 24) to 118.11, marking an increase of 4.78.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 118.11. It has increased from 113.33 (Mar 24) to 118.11, marking an increase of 4.78.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 103.09. It has increased from 91.30 (Mar 24) to 103.09, marking an increase of 11.79.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 21.92. This value is within the healthy range. It has increased from 17.30 (Mar 24) to 21.92, marking an increase of 4.62.
- For PBIT / Share (Rs.), as of Mar 25, the value is 16.81. This value is within the healthy range. It has increased from 12.76 (Mar 24) to 16.81, marking an increase of 4.05.
- For PBT / Share (Rs.), as of Mar 25, the value is 13.19. This value is within the healthy range. It has increased from 11.24 (Mar 24) to 13.19, marking an increase of 1.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 10.57. This value is within the healthy range. It has increased from 8.42 (Mar 24) to 10.57, marking an increase of 2.15.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.26. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 10.26, marking an increase of 2.33.
- For PBDIT Margin (%), as of Mar 25, the value is 21.26. This value is within the healthy range. It has increased from 18.94 (Mar 24) to 21.26, marking an increase of 2.32.
- For PBIT Margin (%), as of Mar 25, the value is 16.30. This value is within the healthy range. It has increased from 13.97 (Mar 24) to 16.30, marking an increase of 2.33.
- For PBT Margin (%), as of Mar 25, the value is 12.79. This value is within the healthy range. It has increased from 12.30 (Mar 24) to 12.79, marking an increase of 0.49.
- For Net Profit Margin (%), as of Mar 25, the value is 10.25. This value exceeds the healthy maximum of 10. It has increased from 9.22 (Mar 24) to 10.25, marking an increase of 1.03.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.94. This value is within the healthy range. It has increased from 8.68 (Mar 24) to 9.94, marking an increase of 1.26.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.68. This value is below the healthy minimum of 15. It has increased from 7.81 (Mar 24) to 8.68, marking an increase of 0.87.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.50. This value is within the healthy range. It has increased from 9.52 (Mar 24) to 10.50, marking an increase of 0.98.
- For Return On Assets (%), as of Mar 25, the value is 5.65. This value is within the healthy range. It has increased from 4.50 (Mar 24) to 5.65, marking an increase of 1.15.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has increased from 0.09 (Mar 24) to 0.23, marking an increase of 0.14.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.11 (Mar 24) to 0.24, marking an increase of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.57. It has increased from 0.53 (Mar 24) to 0.57, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1.5. It has increased from 0.44 (Mar 24) to 0.91, marking an increase of 0.47.
- For Quick Ratio (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has increased from 0.41 (Mar 24) to 0.84, marking an increase of 0.43.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 69.89. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 69.89, marking an increase of 69.89.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.99. This value is below the healthy minimum of 20. It has decreased from 12.60 (Mar 24) to 9.99, marking a decrease of 2.61.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.67. This value is below the healthy minimum of 20. It has decreased from 8.01 (Mar 24) to 6.67, marking a decrease of 1.34.
- For Earning Retention Ratio (%), as of Mar 25, the value is 90.01. This value exceeds the healthy maximum of 70. It has increased from 87.40 (Mar 24) to 90.01, marking an increase of 2.61.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.33. This value exceeds the healthy maximum of 70. It has increased from 91.99 (Mar 24) to 93.33, marking an increase of 1.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.97. This value is within the healthy range. It has decreased from 9.97 (Mar 24) to 8.97, marking a decrease of 1.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.81. This value is within the healthy range. It has increased from 5.73 (Mar 24) to 5.81, marking an increase of 0.08.
- For Enterprise Value (Cr.), as of Mar 25, the value is 54,674.02. It has increased from 32,853.83 (Mar 24) to 54,674.02, marking an increase of 21,820.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.03. This value exceeds the healthy maximum of 3. It has increased from 4.77 (Mar 24) to 7.03, marking an increase of 2.26.
- For EV / EBITDA (X), as of Mar 25, the value is 33.04. This value exceeds the healthy maximum of 15. It has increased from 25.16 (Mar 24) to 33.04, marking an increase of 7.88.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 6.78. This value exceeds the healthy maximum of 3. It has increased from 4.60 (Mar 24) to 6.78, marking an increase of 2.18.
- For Retention Ratios (%), as of Mar 25, the value is 90.00. This value exceeds the healthy maximum of 70. It has increased from 87.39 (Mar 24) to 90.00, marking an increase of 2.61.
- For Price / BV (X), as of Mar 25, the value is 5.91. This value exceeds the healthy maximum of 3. It has increased from 4.14 (Mar 24) to 5.91, marking an increase of 1.77.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 6.78. This value exceeds the healthy maximum of 3. It has increased from 4.60 (Mar 24) to 6.78, marking an increase of 2.18.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fortis Healthcare Ltd:
- Net Profit Margin: 10.25%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.5% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.68% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.81
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.84
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 67.6 (Industry average Stock P/E: 92.72)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.24
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.25%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Fortis Hospital, Sector 62, Phase - VIII, Mohali Punjab 160062 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Ashutosh Raghuvanshi | Managing Director & CEO |
| Ms. Suvalaxmi Chakraborty | Independent Director |
| Mr. Indrajit Banerjee | Independent Director |
| Ms. Shailaja Chandra | Independent Director |
| Mr. Tomo Nagahiro | Non Executive Director |
| Mr. Dilip Kadambi | Non Executive Director |
| Mr. Lim Tsin Lin | Non Executive Director |
| Mr. Mehmet Ali Aydinlar | Non Executive Director |
| Dr. Prem Kumar Nair | Non Executive Director |
| Mr. Ashok Pandit | Non Executive Director |
| Mr. Leo Puri | Chairman & Ind.Director |
FAQ
What is the intrinsic value of Fortis Healthcare Ltd?
Fortis Healthcare Ltd's intrinsic value (as of 27 December 2025) is 683.51 which is 24.22% lower the current market price of 902.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 68,127 Cr. market cap, FY2025-2026 high/low of 1,105/521, reserves of ₹8,674 Cr, and liabilities of 15,013 Cr.
What is the Market Cap of Fortis Healthcare Ltd?
The Market Cap of Fortis Healthcare Ltd is 68,127 Cr..
What is the current Stock Price of Fortis Healthcare Ltd as on 27 December 2025?
The current stock price of Fortis Healthcare Ltd as on 27 December 2025 is 902.
What is the High / Low of Fortis Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fortis Healthcare Ltd stocks is 1,105/521.
What is the Stock P/E of Fortis Healthcare Ltd?
The Stock P/E of Fortis Healthcare Ltd is 67.6.
What is the Book Value of Fortis Healthcare Ltd?
The Book Value of Fortis Healthcare Ltd is 125.
What is the Dividend Yield of Fortis Healthcare Ltd?
The Dividend Yield of Fortis Healthcare Ltd is 0.11 %.
What is the ROCE of Fortis Healthcare Ltd?
The ROCE of Fortis Healthcare Ltd is 12.0 %.
What is the ROE of Fortis Healthcare Ltd?
The ROE of Fortis Healthcare Ltd is 10.1 %.
What is the Face Value of Fortis Healthcare Ltd?
The Face Value of Fortis Healthcare Ltd is 10.0.